11 July 2016 - The ICER has set its sights on a new target: life-saving treatments for advanced non-small cell lung cancer.

ICER’s latest draft scoping document outlines what it will cover in its forthcoming report assessing treatments for advanced non-small cell lung cancer (NSCLC). According to the scoping document, ICER’s evidence report will assess several categories of lung cancer treatments, including tyrosine kinase inhibitors (TKIs) and immunotherapies. The value of these treatments in the fight against NSCLC, which accounts for 85 to 90 percent of all lung cancer diagnoses, has been widely recognized.

Since 2014, ICER has been issuing assessment reports that threaten patient access to life-saving treatments for debilitating and devastating conditions, such as congestive heart failure, multiple myeloma and diabetes, among others. ICER’s reports have historically relied on flawed methods and assumptions, lacked transparency and failed to reflect the complex realities of optimally caring for patients with these conditions.

View PhRMA Commentary